IL6 and pancreatic neoplasm: Our previous study showed that Raloxifene selectively inhibits STAT3 phosphorylation induced by IL-6 in the GP130/JAK/STAT3 signaling pathway in pancreatic cancer cell-lines (PANC-1) that express GP130, but not ER [16].